Medicine
Duobrii 0.1 mg/0.45 mg per g lotion
Duobrii 0.1 mg/0.45 mg per g lotion is a prescription medicine containing Halobetasol propionate and Tazarotene for topical use, marketed by Bausch Health, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Protect from freezing. Store at 20° to 25°C (68° to 77°F), excursions…
Key facts
- Active ingredient (INN)
- Halobetasol propionate and Tazarotene
- Brand
- Duobrii
- Strength
- 0.1 mg/0.45 mg per g
- Dosage form
- Lotion
- Route
- Topical
- Packs
- 1 tube
- Marketing authorisation holder
- Bausch Health
- Manufacturer
- Bausch Health
- Origin register
- US FDA, United States
- Storage
- Protect from freezing. Store at 20° to 25°C (68° to 77°F), excursions permitted to 15° to 30°C (59° to 86°F).
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- HS code (indicative)
- 3004.32Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 25 April 2019
- Identifiers
- RxCUI 2166089, 2166094DailyMed set ID b3f0cdc0-69fd-43d1-baf2-d776a3a20715NDC 0187-0653Application NDA209354
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 1 tube in 1 carton / 100 g in 1 tube | 0187-0653-01 | Bausch Health | 25 April 2019 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| US FDA | First approved 25 April 2019 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Clinical summary
Halobetasol propionate and Tazarotene is a fixed-dose combination of a corticosteroid and a retinoid indicated for the topical treatment of plaque psoriasis in adults. It is available as lotion for topical use. MedsAcross supplies Halobetasol propionate and Tazarotene for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about Halobetasol propionate and TazaroteneFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Duobrii prescribing information (Bausch Health) · U.S. National Library of Medicine, DailyMed
Need Duobrii 0.1 mg/0.45 mg per g lotion for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.